Evidence map›Paper›PMID 36397282›Full record

ArticleJournal of clinical laboratory analysis2022

Molecular epidemiology and clinical characteristics of Clostridioides difficile infection in patients with inflammatory bowel disease from a teaching hospital.

Yan-Ming Li, Jing-Zhong Liao, Zi-Juan Jian, Hong-Ling Li, Xia Chen, Qing-Xia Liu, Pei-Lin Liu, Zhi-Qian Wang, Xuan Liu, Qun Yan and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Global Patterns ofCrohn's & colitis 360 · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yan-Ming LiDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-1509-0953
Jing-Zhong LiaoDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Zi-Juan JianDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Hong-Ling LiDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0001-8778-7050
Xia ChenDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Qing-Xia LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Pei-Lin LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0001-9822-4587
Zhi-Qian WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Xuan LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Qun YanDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Wen-En LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CN

Funding

Development and Reform Commission of Hunan Province 2019875Science and Technology Program of Hunan Province 2015SK2018
6 · The paper itself

Abstract

backgroundClostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is of increasing concern. This study aimed to investigate the molecular epidemiology and antimicrobial susceptibilities of toxigenic C. difficile isolated from IBD patients and to evaluate the risk factors for CDI in IBD population.

methodsLoose or watery stools from IBD patients were tested for glutamate dehydrogenase, C. difficile toxins A&B and anaerobic culture. Toxigenic C. difficile isolates were characterized by multi-locus sequence typing, ribotyping and antimicrobial susceptibility testing.

resultsThe prevalence of CDI in IBD patients was 13.6% (43/317). The dominant sequence types (STs) were ST35 (20.9%), ST2 (18.6%) and ST37 (16.3%). The most common ribotypes (RTs) were RT 017 (18.6%), RT 012 (14.0%), and RT 220 (14.0%), whereas RT 027 and RT 078 were not detected in this study. All the isolates were susceptible to vancomycin and metronidazole. The multidrug resistance rate of C. difficile RT 017 was higher (p < 0.01) than that of other RT strains. Recent hospitalization, use of corticosteroids and proton pump inhibitors were related to increased risk of CDI in IBD patients; of these, recent hospitalization and proton pump inhibitors use were independent risk factors.

conclusionPatients with IBD have a relatively high incidence rate of CDI. C. difficile RT 017 is most frequently isolated from IBD patients in this region and warrants more attention to its high resistance rate. Clinicians should pay greater attention to CDI testing in IBD patients with diarrhea to ensure early diagnosis and initiation of effective treatment.

Indexed as

Anti-Infective AgentsClostridioides difficileClostridium InfectionsInflammatory Bowel DiseasesAnti-Bacterial AgentsDiarrheaHospitals, TeachingHumansMolecular EpidemiologyMultilocus Sequence TypingProton Pump InhibitorsAnti-Bacterial AgentsAnti-Infective AgentsProton Pump Inhibitorsantimicrobial resistanceClostridioides difficile infectioninflammatory bowel diseasemulti-locus sequence typingribotyperisk factors

Identifiers

PMID36397282
PMCPMC9757003
OpenAlexW4309366690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.